Drug Profile
Vintafolide - Endocyte
Alternative Names: EC-145; Folic acid desacetylvinblastine hydrazine conjugate; MK-8109; VYNFINITLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Endocyte
- Class Amino acids; Antineoplastics; Folic acids; Hydrazines; Pterins; Sulfhydryl compounds; Vinca alkaloids
- Mechanism of Action Microtubule protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Submission Withdrawal Ovarian cancer
- No development reported Non-small cell lung cancer; Solid tumours
- Discontinued Endometrial cancer
Most Recent Events
- 06 Aug 2019 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Monotherapy, Second-line therapy or greater) in Poland, Germany, France, Spain, Russia, Romania, Hungary, Czech Republic, United Kingdom, Bulgaria, USA (IV) (Endocyte website, August 2019)
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 07 Sep 2015 Final efficacy and adverse events data from a phase II trial in Non Small Cell Lung Cancer released by Endocyte